Table 2.
Reference | Type of study | Best marker/subregion | Country | Subjects | Significance |
---|---|---|---|---|---|
Sawcer et al. (1996) | Linkage | d19s246/19q13.4 | UK | 227 multiplex families | LOD=1 |
Haines et al. (1996) | Linkage | d19s219/19q13.2 | USA | 52 multiplex families | LOD=1.13 |
Ebers et al. (1996) | Linkage | d19s47/19q13.2 | Canada | 100 sibling pairs | LOD=0.73 |
Kuokkanen et al. (1997) | Linkage | d19s246/19q13.4 | Finland | 16 multiples families | LOD=1 |
D’Alfonso et al. (1999) | Linkage | 19q13.3 | Italy | 69 families | LOD<0.7 |
Coraddu et al. (2001) | Linkage | 19q13 | Italy/Sardinia | 49 multiplex families | LOD<0.7 |
Broadley et al. (2001) | Linkage | 19q13 | Italy | 40 multiplex families | LOD<0.7 |
Green et al. (2001) | Linkage | CEA/19q13.2 | USA | 161 multiplex | LOD=1.25 |
Xu et al. (2001) | Linkage | D19S246/19q13.4 | Sweden | 46 multiplex families | NPL score -0.46 |
Reunanen et al. (2002) | Linkage | d19s876/19q13.1 | Finland | 27 multiplex families | LOD=1.8 |
Haines et al. (2002) | Linkage | d19s879/19q13.4 | USA | 98 multiplex families | LOD=3.01 |
Lucotte et al. (2002) | Linkage | 19q13.3 | France | 18 multiplex families | LOD=2.1 |
Pericak-Vance et al. (2004) | Linkage | D19S217/19q13.2 | USA | 98 multiplex families | LOD=2.17 |
Pericak-Vance et al. (2004) | Linkage | D19S217/19q13.2 | USA | 53 families, HLA-DR15+ | LOD=2.37 |
Pericak-Vance et al. (2004) | Linkage | D19S217/19q13.2 | France | 90 families | LOD<0.7 |
Haghighi et al. (2006) | Linkage with OCBa | D2S219/19q13.2 | Sweden | 2 extended families | LOD=1.8 |
Schmidt et al. (2002) | Association | APOE ε2-haplotype | USA | 328 families | p=0.005 |
Yeo et al. (2003) | Association | d19s585/19q13.4 | UK | 961 patients | p=0.12 |
Ban et al. (2003) | Association | d19s219/19q13.2 | Australia | 217 patients | p=0.009 |
Koch et al. (2005) | Association | ILT6/19q13.4 | Germany, France | 751 patients | p=0.009 |
Burwick et al. (2006) | Association | APOE/19q13.2 | Meta-analysis | 3200 patients | p>0.05 |
Burton et al. (2007) | Association | ZNF45 and GIPR/19q13.2 | UK | 1000 patients | p=0.00005 and p=0.0008 |
Hafler et al. (2007) | Associationb | MAG, CD22, TYROBP/19q13.1c | UK, USA | 931 trios/2431 controls | p>0.05 |
Hafler et al. (2007) | Associationb | APOE, ZNF45, GIPR/19q13.2c | UK, USA | 931 trios/2431 controls | p>0.05 |
Hafler et al. (2007) | Associationb | synaptogyrin4/13q13.3d | UK, USA | 931 trios/2431 controls | p=0.02/0.0003 |
Hafler et al. (2007) | Associationb | ZNF577/19q13.4d | UK, USA | 931 trios/2431 controls | p=0.04/0.001 |
OCB = oligoclonal bands in cerebrospinal fluid.
We search for association on chromosome 19q13 between positions 40 Mb and 60 Mb for the following criteria: TDT statistics have a p-value<0.05 or CMH statistics have a p-value<0.001 (https://imsgc.org/php/results.php).
The 19q13.1 region harbouring MAG, CD22, TYROBP (40-42 Mb) and the 19q13.2 region harbouring APOE, ZNF45 and GIPR (49-51 Mb) were analysed with 128 and 177 markers, respectively, all of which failed to show any association (in both TDT and CMH statistics).
These markers fulfilled the association criteria.